Key Takeaways
- Zoetis shares plummeted 20% to $88.94 Thursday, marking the session’s worst S&P 500 performer
- First-quarter earnings of $1.53 per share fell short of the $1.60 analyst estimate; revenue of $2.26B missed the $2.3B forecast
- Full-year earnings guidance reduced to $6.85–$7.00 from previous $7.00–$7.10 range
- Management highlighted growing price sensitivity among pet owners and declining veterinary clinic traffic
- Analysts at Stifel noted results appear worse than headline numbers suggest due to $100M one-time revenue adjustment
Shares of Zoetis (ZTS) tumbled 20% to $88.94 Thursday, landing at the bottom of the S&P 500 performance rankings. Data from Dow Jones Market Data indicates the stock is tracking toward its weakest closing price in more than seven years, with year-to-date losses now reaching 29%.
The sharp decline followed the animal healthcare company’s disappointing first-quarter financial report, which fell short of expectations across key metrics.
First-quarter profit reached $1.53 per share, representing growth from $1.48 in the prior-year period but missing the Street’s $1.60 target. Top-line results showed 3% year-over-year expansion to $2.26 billion, still beneath the $2.3 billion analyst projection compiled by FactSet.
Chief Executive Kristin Peck acknowledged the quarter unfolded in a more challenging landscape than anticipated. Pet owners have become increasingly cost-conscious, resulting in reduced veterinary appointments and diminished appetite for higher-priced offerings.
Domestic revenue declined approximately 8% year-over-year to $1.1 billion. Sales of companion animal products in the United States fell roughly 11%, pressured by softer consumer demand and competitive dynamics.
Overseas Operations Provided Partial Offset
Revenue from international markets expanded 17% year-over-year to $1.1 billion, supported by a 10% increase in companion animal product demand. The company’s parasiticide product line served as a primary growth catalyst in these regions.
Notably, the international figure incorporated approximately $100 million in sales accelerated due to a fiscal reporting calendar adjustment. The firm removed a one-month reporting delay for international subsidiaries, creating a temporary first-quarter boost that won’t recur in future periods.
Wall Street Analysts Flag Deeper Concerns
Stifel’s Jonathan Block and his research team characterized the first-quarter performance as “worse than it seems” upon closer examination. After accounting for the $100 million timing-related benefit, underlying organic operational revenue growth significantly underperformed market expectations.
Block’s analysis highlighted “notable weakness” specifically within the companion animal business as a source of concern moving forward.
In response to current headwinds, Zoetis reduced its full-year 2026 projections. Adjusted earnings per share guidance now stands at $6.85 to $7.00, retreating from the earlier $7.00 to $7.10 forecast. Street consensus had been centered at $7.03.
The company also trimmed revenue expectations to a range of $9.68 billion to $9.96 billion, down from the previous $9.825 billion to $10.025 billion band. Analyst consensus stood at $9.89 billion.
Peck stated the organization is implementing “decisive action to sharpen commercial execution, unlock revenue, and continue to drive disciplined cost management.”
The stock’s 20% single-session plunge has pushed ZTS to price levels last witnessed in early 2019.
The adjusted profit of $1.53 per share represented approximately 9% year-over-year growth, yet still lagged consensus projections by $0.09.
Thursday’s collapse extends the stock’s full-year decline to 29%, representing a difficult period for an equity previously regarded as a reliable growth story within the healthcare sector.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
